fluoxetine has been researched along with Smoking Cessation in 21 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Smoking Cessation: Discontinuing the habit of SMOKING.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Furthermore, sequential fluoxetine treatment, compared with standard fluoxetine treatment, resulted in significantly lower levels of depressive symptoms throughout smoking cessation treatment (p < ." | 9.19 | Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers. ( Abrantes, AM; Brown, RA; Kahler, CW; Miller, IW; Niaura, R; Price, LH; Strong, DR, 2014) |
| "Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder." | 9.11 | Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. ( Borrelli, B; Cook, JW; Hitsman, B; Keuthen, NJ; Kristeller, J; McChargue, DE; Niaura, R; Spring, B, 2004) |
| "The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation." | 9.10 | Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. ( Abrams, DB; Borrelli, B; Chiles, JA; DePue, J; Goldstein, MG; Hedeker, D; Keuthen, N; Kristeller, J; Niaura, R; Ockene, J; Prochazka, A; Spring, B, 2002) |
| "The authors examined whether serum fluoxetine levels influence behavioral treatment adherence and smoking cessation outcome." | 9.09 | Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine. ( Borrelli, B; Hitsman, B; Niaura, R; Papandonatos, GD; Spring, B, 2001) |
| "We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking." | 9.08 | Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995) |
| "The effect of fluoxetine hydrochloride, a 5-HT uptake inhibitor (60 mg/day PO), in preventing weight gain associated with nicotine reduction was investigated in participants in a double-blind, placebo-controlled smoking-cessation trial." | 9.07 | Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake. ( Lowenbergh, JM; Morrell, EM; Pomerleau, CS; Pomerleau, OF, 1991) |
| "Fluoxetine appeared to increase abstinence rates among high BDI smokers compared to high BDI smokers assigned placebo." | 6.69 | The effects of fluoxetine combined with nicotine inhalers in smoking cessation--a randomized trial. ( Bjornsdottir, US; Blondal, T; Gudmundsson, LJ; Hilmarsdottir, H; Jonsdottir, D; Kristjansson, F; Nilsson, F; Tomasson, K, 1999) |
| " Furthermore, sequential fluoxetine treatment, compared with standard fluoxetine treatment, resulted in significantly lower levels of depressive symptoms throughout smoking cessation treatment (p < ." | 5.19 | Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers. ( Abrantes, AM; Brown, RA; Kahler, CW; Miller, IW; Niaura, R; Price, LH; Strong, DR, 2014) |
| "The present study, a secondary analysis of published data, assessed (a) the influence of initial positive mood (PM) on smoking cessation and (b) whether smokers low in PM benefited from fluoxetine versus placebo for cessation." | 5.12 | Elevated positive mood: a mixed blessing for abstinence. ( Borrelli, B; Doran, N; Hedeker, D; Hitsman, B; McChargue, D; Niaura, R; Spring, B, 2006) |
| "Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder." | 5.11 | Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. ( Borrelli, B; Cook, JW; Hitsman, B; Keuthen, NJ; Kristeller, J; McChargue, DE; Niaura, R; Spring, B, 2004) |
| "A quasi-experimental secondary analysis of data collected from a randomized placebo-controlled trial of fluoxetine (60 mg or 30 mg) versus placebo for smoking cessation." | 5.11 | Experimenter-defined quit dates for smoking cessation: adherence improves outcomes for women but not for men. ( Borrelli, B; Hitsman, B; Niaura, R; Papandonatos, G; Spring, B, 2004) |
| "Fluoxetine's effect (30 mg, 60 mg, and placebo) on postcessation weight gain was studied among participants from a randomized, double-blind 10-week smoking cessation trial who met strict criteria for abstinence and drug levels." | 5.09 | Weight suppression and weight rebound in ex-smokers treated with fluoxetine. ( Borrelli, B; Keuthen, NJ; Kristeller, J; Niaura, R; Ockene, JK; Spring, B, 1999) |
| "Adult smokers (N = 253) without clinically significant depression were randomized on a double-blind basis to receive fluoxetine (30 or 60 mg daily) or a placebo for 10 weeks in combination with cognitive-behavioral therapy (CBT)." | 5.09 | Antidepressant pharmacotherapy helps some cigarette smokers more than others. ( Hitsman, B; Kristeller, JL; Mahableshwarkar, A; Mizes, JS; Pingitore, R; Segraves, KA; Spring, B; Xu, W, 1999) |
| " The authors of this study investigated predictors of relapse among 989 participants (60% women) in a randomized, double-blind, 10-week multicenter trial to determine the effect of fluoxetine (30 or 60 mg) versus placebo in combination with behavioral counseling for smoking cessation." | 5.09 | Influences of gender and weight gain on short-term relapse to smoking in a cessation trial. ( Borrelli, B; Hitsman, B; Niaura, R; Papandonatos, G; Spring, B, 2001) |
| "We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking." | 5.08 | Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995) |
| "Two smoking cessation studies provided venues to 1) look for differences in affective symptoms between cigarette smokers with and without a history of major depression or other psychiatric diagnoses who were not currently depressed and 2) evaluate the efficacy of fluoxetine in ameliorating affective symptoms in smokers with a history of major depression but not currently depressed." | 5.08 | Mood, major depression, and fluoxetine response in cigarette smokers. ( Covey, L; Dalack, GW; Glassman, AH; Rivelli, S; Stetner, F, 1995) |
| "Nondepressed participants (N = 114) in a trial investigating the effect of fluoxetine on smoking cessation were administered the Structured Clinical Interview for DSM-III-R at baseline and posttreatment to evaluate the impact of quitting smoking on the development of MDD." | 5.08 | Development of major depressive disorder during smoking-cessation treatment. ( Abrams, DB; Borrelli, B; DePue, JD; Goldstein, MG; Keuthen, NJ; Murphy, C; Niaura, R, 1996) |
| "The effect of fluoxetine hydrochloride, a 5-HT uptake inhibitor (60 mg/day PO), in preventing weight gain associated with nicotine reduction was investigated in participants in a double-blind, placebo-controlled smoking-cessation trial." | 5.07 | Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake. ( Lowenbergh, JM; Morrell, EM; Pomerleau, CS; Pomerleau, OF, 1991) |
| " The three case studies are (1) bupropion versus nicotine replacement therapy for smoking cessation, (2) risperidone versus haloperidol for schizophrenia, and (3) fluoxetine versus imipramine for depressive disorders." | 4.84 | Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. ( Harvey, I; Lilford, R; Song, F, 2008) |
| " Dosing order was determined randomly and counterbalanced." | 2.70 | Subjective and discriminative stimulus effects of two de-nicotinized cigarettes with different tar yields. ( Downey, KK; Schuh, KJ; Schuh, LM; Stamat, HM, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (42.86) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, EJ | 1 |
| Felsovalyi, K | 1 |
| Young, LM | 1 |
| Shmelkov, SV | 1 |
| Grunebaum, MF | 1 |
| Cardozo, T | 1 |
| Brown, RA | 1 |
| Abrantes, AM | 1 |
| Strong, DR | 1 |
| Niaura, R | 9 |
| Kahler, CW | 1 |
| Miller, IW | 1 |
| Price, LH | 1 |
| Nanchen, D | 1 |
| Willi, C | 1 |
| Peytremann-Bridevaux, I | 1 |
| Burnand, B | 1 |
| Walther, MR | 1 |
| Spring, B | 9 |
| Borrelli, B | 8 |
| Hedeker, D | 2 |
| Goldstein, MG | 2 |
| Keuthen, N | 1 |
| DePue, J | 1 |
| Kristeller, J | 3 |
| Ockene, J | 1 |
| Prochazka, A | 1 |
| Chiles, JA | 1 |
| Abrams, DB | 2 |
| Cook, JW | 1 |
| McChargue, DE | 1 |
| Hitsman, B | 6 |
| Keuthen, NJ | 3 |
| Papandonatos, G | 2 |
| Doran, N | 1 |
| McChargue, D | 1 |
| Song, F | 1 |
| Harvey, I | 1 |
| Lilford, R | 1 |
| Wurtman, J | 1 |
| Wurtman, R | 1 |
| el-Khoury, A | 1 |
| Goldberg, H | 1 |
| McDermott, J | 1 |
| Pingitore, R | 2 |
| Dalack, GW | 1 |
| Glassman, AH | 1 |
| Rivelli, S | 1 |
| Covey, L | 1 |
| Stetner, F | 1 |
| Dimitsopulos, T | 1 |
| Kurlan, R | 1 |
| DePue, JD | 1 |
| Murphy, C | 1 |
| Ockene, JK | 1 |
| Cornelius, JR | 1 |
| Perkins, KA | 1 |
| Salloum, IM | 1 |
| Thase, ME | 1 |
| Moss, HB | 1 |
| Mahableshwarkar, A | 1 |
| Mizes, JS | 1 |
| Segraves, KA | 1 |
| Kristeller, JL | 1 |
| Xu, W | 1 |
| Blondal, T | 1 |
| Gudmundsson, LJ | 1 |
| Tomasson, K | 1 |
| Jonsdottir, D | 1 |
| Hilmarsdottir, H | 1 |
| Kristjansson, F | 1 |
| Nilsson, F | 1 |
| Bjornsdottir, US | 1 |
| Rasmussen, K | 1 |
| Calligaro, DO | 1 |
| Czachura, JF | 1 |
| Dreshfield-Ahmad, LJ | 1 |
| Evans, DC | 1 |
| Hemrick-Luecke, SK | 1 |
| Kallman, MJ | 1 |
| Kendrick, WT | 1 |
| Leander, JD | 1 |
| Nelson, DL | 1 |
| Overshiner, CD | 1 |
| Wainscott, DB | 1 |
| Wolff, MC | 1 |
| Wong, DT | 1 |
| Branchek, TA | 1 |
| Zgombick, JM | 1 |
| Xu, YC | 1 |
| Schuh, LM | 1 |
| Stamat, HM | 1 |
| Downey, KK | 1 |
| Schuh, KJ | 1 |
| Papandonatos, GD | 1 |
| Pomerleau, OF | 1 |
| Pomerleau, CS | 1 |
| Morrell, EM | 1 |
| Lowenbergh, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00113737] | 0 participants | Interventional | 1998-02-28 | Completed | |||
| [NCT00113711] | 0 participants | Interventional | 1995-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluoxetine and Smoking Cessation
| Article | Year |
|---|---|
Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bias; Bupropion; Data Interpretation | 2008 |
16 trials available for fluoxetine and Smoking Cessation
| Article | Year |
|---|---|
Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Behavior Therapy; Combined Modali | 2014 |
Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Double-Blind Method; Female; Fluoxetine; Humans; | 2002 |
Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Moda | 2004 |
Experimenter-defined quit dates for smoking cessation: adherence improves outcomes for women but not for men.
Topics: Adolescent; Adult; Aged; Behavior Therapy; Female; Fluoxetine; Humans; Male; Middle Aged; Patient Co | 2004 |
Elevated positive mood: a mixed blessing for abstinence.
Topics: Adolescent; Adult; Affect; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; | 2006 |
Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation.
Topics: Adult; Analysis of Variance; Appetite Depressants; Body Mass Index; Dietary Carbohydrates; Dietary P | 1995 |
Mood, major depression, and fluoxetine response in cigarette smokers.
Topics: Adult; Affective Symptoms; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Fluoxetine | 1995 |
Development of major depressive disorder during smoking-cessation treatment.
Topics: Behavior Therapy; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Male; Middle Aged; P | 1996 |
Weight suppression and weight rebound in ex-smokers treated with fluoxetine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Midd | 1999 |
Weight suppression and weight rebound in ex-smokers treated with fluoxetine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Midd | 1999 |
Weight suppression and weight rebound in ex-smokers treated with fluoxetine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Midd | 1999 |
Weight suppression and weight rebound in ex-smokers treated with fluoxetine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Midd | 1999 |
Fluoxetine versus placebo to decrease the smoking of depressed alcoholic patients.
Topics: Adult; Alcoholism; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middl | 1999 |
Antidepressant pharmacotherapy helps some cigarette smokers more than others.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Com | 1999 |
The effects of fluoxetine combined with nicotine inhalers in smoking cessation--a randomized trial.
Topics: Adult; Aged; Algorithms; Antidepressive Agents, Second-Generation; Double-Blind Method; Drug Therapy | 1999 |
Subjective and discriminative stimulus effects of two de-nicotinized cigarettes with different tar yields.
Topics: Adult; Blood Pressure; Female; Fluoxetine; Heart Rate; Humans; Male; Middle Aged; Nicotine; Selectiv | 2001 |
Influences of gender and weight gain on short-term relapse to smoking in a cessation trial.
Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Dose-Response Relationship, Drug; Do | 2001 |
Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior Therapy; Combined Modality Therapy; Dose-R | 2001 |
Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake.
Topics: Adult; Cacao; Cotinine; Double-Blind Method; Eating; Female; Fluoxetine; Humans; Male; Middle Aged; | 1991 |
4 other studies available for fluoxetine and Smoking Cessation
| Article | Year |
|---|---|
Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Fluoxetine; Ganglia, Spinal; Humans | 2018 |
[Preventing weight gain in smoking cessation: there is no miracle solution].
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Fluoxetine; Humans; | 2009 |
Tourette's syndrome and nicotine withdrawal.
Topics: Adult; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Smoking Cessation; Tourette Syndro | 1993 |
The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acoustic Stimulation; Animals; Body Temperature; Columbidae; | 2000 |